Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Xiao‐Han Tang, Xiushuang Zheng, Bowen Gong, Meisong Lu, Hao Ran Li
Abstract
Authors
Institutions
Provenance
crossref
No local reference links have been materialized yet.
10.3322/caac.21660
10.3322/caac.21660
10.3322/caac.21654
10.3322/caac.21654
10.1038/s41568-019-0177-x
10.1038/s41568-019-0177-x
Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers
10.1200/jco.19.00151 · 2019
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study
10.1200/jco.2004.07.184 · 2004
Current recommendations and recent progress in endometrial cancer
2019
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer
10.1016/j.ygyno.2018.05.018 · 2018
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
10.1158/1078-0432.ccr-20-0953 · 2020
Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
10.1016/j.fertnstert.2011.07.1146 · 2011
Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia - A systematic quantitative review
10.1001/jama.288.13.1610 · 2002
10.1016/s0140-6736(15)00130-0
10.1016/s0140-6736(15)00130-0
BGCS uterine cancer guidelines: Recommendations for practice
10.1016/j.ejogrb.2017.04.015 · 2017
10.1038/ng.3562
10.1038/ng.3562
Identification of nine new susceptibility loci for endometrial cancer
10.1038/s41467-018-05427-7 · 2018
Genome-Wide Association Studies of Endometrial Cancer: Latest Developments and Future Directions
10.1158/1055-9965.epi-18-1031 · 2019
10.1002/1878-0261.12727
10.1002/1878-0261.12727
10.1371/journal.pmed.1002206
10.1371/journal.pmed.1002206
10.1126/science.aal2380
10.1126/science.aal2380
10.1016/j.cell.2007.02.005
10.1016/j.cell.2007.02.005
Comparative DNA methylome analysis of endometrial carcinoma reveals complex and distinct deregulation of cancer promoters and enhancers
10.1186/1471-2164-15-868 · 2014
Status and significance of CpG island methylator phenotype in endometrial cancer
10.1159/000324496 · 2011
Assessing sirtuin expression in endometrial carcinoma and non-neoplastic endometrium
10.18632/oncotarget.6691 · 2016
Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors
10.1016/j.bios.2019.111386 · 2019
Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma
10.3892/ol.2014.2437 · 2014
10.18632/oncotarget.6350
10.18632/oncotarget.6350
Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma
2012
Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma
10.1016/j.ygyno.2012.07.128 · 2013
10.1038/nature05915
10.1038/nature05915
The chromatin accessibility landscape of primary human cancers
10.1126/science.aav1898 · 2018
An integrative analysis of TFBS-clustered regions reveals new transcriptional regulation models on the accessible chromatin landscape
2015
10.1093/bioinformatics/btx282
10.1093/bioinformatics/btx282
Functional annotation of HOT regions in the human genome: implications for human disease and cancer
2015
TRANSFAC: an integrated system for gene expression regulation
10.1093/nar/28.1.316 · 2000
10.1093/nar/gkp950
10.1093/nar/gkp950
10.1093/nar/gkq992
10.1093/nar/gkq992
iFORM: Incorporating Find Occurrence of Regulatory Motifs
10.1371/journal.pone.0168607 · 2016
10.1038/s41576-019-0114-6
10.1038/s41576-019-0114-6
10.1016/j.cell.2017.09.042
10.1016/j.cell.2017.09.042
10.1038/s41586-020-2214-z
10.1038/s41586-020-2214-z
10.1038/nature12113
10.1038/nature12113
10.1093/nar/gky1025
10.1093/nar/gky1025 · doi-reference
10.1038/s41588-019-0494-8
10.1038/s41588-019-0494-8 · doi-reference
Mutational Landscape and Antiproliferative Functions of ELF Transcription Factors in Human Cancer
10.1158/0008-5472.can-14-3816 · doi-reference
ITE, an endogenous aryl hydrocarbon receptor ligand, suppresses endometrial cancer cell proliferation and migration
10.1016/j.tox.2019.03.017 · doi-reference
Expression of NRP-1 and NRP-2 in Endometrial Cancer
10.2174/1389201020666190219121602 · doi-reference
PRSS8 is Downregulated and Suppresses Tumour Growth and Metastases in Hepatocellular Carcinoma
10.1159/000453136 · doi-reference
UBE2C Is Upregulated by Estrogen and Promotes Epithelial-Mesenchymal Transition via p53 in Endometrial Cancer
10.1158/1541-7786.mcr-19-0561 · doi-reference
10.1007/s00404-012-2706-7
10.1007/s00404-012-2706-7 · doi-reference
MiR-29a-5p inhibits proliferation and invasion and induces apoptosis in endometrial carcinoma via targeting TPX2
10.1080/15384101.2018.1475829 · doi-reference
10.1038/s41388-018-0453-3
10.1038/s41388-018-0453-3 · doi-reference
Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters
10.1158/1078-0432.ccr-16-2655 · doi-reference
10.1016/j.cell.2016.08.056
10.1016/j.cell.2016.08.056 · doi-reference
10.1038/s41586-020-2023-4
10.1038/s41586-020-2023-4 · doi-reference